Latest Board Oversight News

Page 3 of 3
Elsight Limited has responded to ASX concerns over a premature media report on its $60 million capital raise, denying any unauthorized disclosures and reaffirming its compliance with continuous disclosure rules.
Sophie Babbage
Sophie Babbage
28 July 2025
The Lottery Corporation has appointed Wayne Pickup as its new CEO, succeeding Sue van der Merwe who is retiring after 35 years in the industry. Pickup brings 25 years of global lottery experience and will begin in November 2025, pending regulatory approvals.
Victor Sage
Victor Sage
28 July 2025
I Synergy Group Limited has disclosed a non-binding Memorandum of Understanding following a sharp rise in its share price and trading volume, addressing ASX concerns over market transparency.
Victor Sage
Victor Sage
24 July 2025
West Wits Mining appoints CEO Rudi Deysel as Managing Director and adds Keith Middleton as non-executive director, while veteran board member Hulme Scholes retires after 14 years. These changes come as the company transitions into operational gold production at its Qala Shallows project in South Africa.
Maxwell Dee
Maxwell Dee
14 July 2025
DY6 Metals has addressed an ASX price query by confirming confidential negotiations for acquiring additional mining licenses in Cameroon, explaining recent share price movements and ensuring compliance with continuous disclosure rules.
Maxwell Dee
Maxwell Dee
8 July 2025
Pure Hydrogen Corporation has confirmed that the delivery and formal acceptance of its Taurus Hydrogen Fuel Cell Prime Mover to Barwon Water is material information likely to affect its share price, responding to ASX queries on disclosure timing and compliance.
Maxwell Dee
Maxwell Dee
1 July 2025
Alliance Aviation Services has updated its FY25 financial guidance, aiming for EBITDA between $205-210 million while navigating operational disruptions and planning significant debt reduction by 2026.
Victor Sage
Victor Sage
14 May 2025
Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.
Ada Torres
Ada Torres
14 Feb 2025

Browse the archive

Full archive